Clinicopathologic Implication of Ezrin Expression in Non-small Cell Lung Cancer.
- Author:
Ho Won LEE
1
;
Eui Han KIM
;
Mee Hye OH
Author Information
1. Department of Pathology, Soonchunhyang University College of Medicine, Cheonan, Korea. mhoh0212@hanmail.net
- Publication Type:Original Article
- Keywords:
Carcinoma, non-small cell lung;
Ezrin;
Prognosis
- MeSH:
Carcinoma, Non-Small-Cell Lung;
Cytoskeletal Proteins;
Female;
Humans;
Lung;
Prognosis
- From:Korean Journal of Pathology
2012;46(5):470-477
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Ezrin, a member of the ezrin-radixin-moesin family, is implicated in tumor progression, metastatic dissemination, and adverse outcomes, in several cancer types. In this study, we explored the clinicopathological significance of ezrin expression in non-small cell lung carcinomas (NSCLCs). METHODS: Immunohistochemical analysis of tissue microarray with 112 surgically resected NSCLC specimens, was performed to examine the ezrin expression. We also correlated ezrin expression with other clinicopathological features and prognosis. RESULTS: The ezrin-positive group revealed significantly higher correlation with pleural invasion (p=0.016) and pathologic stage (p=0.050). Univariate survival analysis showed that ezrin-positive group had a significantly shorter cancer-specific survival than ezrin-negative group (p=0.016). Meanwhile, female (p=0.030), no pleural invasion (p=0.023), no lymphatic invasion (p=0.026), and early pathologic stage (p=0.008) significantly correlated with longer survival. Multivariate survival analysis showed that variables such as ezrin positivity (p=0.032), female (p=0.035), and early pathologic stage (p=0.001) were independent prognostic factors for NSCLC. CONCLUSIONS: Ezrin might be a molecular marker to predict poor prognosis of NSCLC.
